Skip to content

Contact +44 (0) 20 7060 7474 email us

Clinical Trials

Disease Specific Markers Clinical Trial Analysis

 

Publication Date July 2009
Publisher Global Markets Direct
Product Type
Pages 80
ISBN Number not applicable
Product Code GMD02885

Price

£660.00
approximately: $999 | €737

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Global Markets Direct's "Disease Specific Markers Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Disease Specific Markers manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

  • The report provides analysis and review of the key clinical trials being carried out globally and across key Disease Specific Markers market categories - Tumour Markers,Cardiac Markers
  • The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
  • The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
  • The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

  • Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
  • Stay ahead of the information curve in the fast changing Disease Specific Markers market.
  • Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
  • Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

  • 1 List of Tables
  • 1.2 List of Figures
  • 2 Disease Specific Markers Clinical Trials
    • 2.1 Disease Specific Markers Clinical Trial By Equipment Type
    • 2.2 Disease Specific Markers Clinical Trials By Trial Phase and Trial Status
    • 2.3 Disease Specific Markers Pipeline Products By Development Stage
    • 2.4 Disease Specific Markers Pipeline Products By Therapy Area
    • 2.5 Disease Specific Markers Pipeline Products By News Summary
    • 2.6 Disease Specific Markers B7-H4 (DD-O110) assay
      • 2.6.1 B7-H4 Is A Novel Membrane-Bound Protein And a Candidate Serum And Tissue Biomarker For Ovarian Cancer
      • 2.6.2 B7-H4 Is Over-Expressed In Early-Stage Ovarian Cancer And Is Independent Of CA125 Expression
    • 2.7 Disease Specific Markers Spondin-2 (DD-P108) assay
      • 2.7.1 Evaluation Of The Novel Serum Marker, Spondin 2, For Diagnosis And Early Detection Of Ovarian Cancer
    • 2.8 Disease Specific Markers DcR3 (DD-C248) assay
      • 2.8.1 Evaluation Of DcR3 For Diagnosis And Early Detection Of Ovarian Cancer
    • 2.9 Disease Specific Markers TRAIL-R2 assay
      • 2.9.1 Trails To Evaluate The Safety And Pharmacology Of Trail-R2 Monoclonal Antibody In Patients With Advanced Tumors
    • 2.10 Disease Specific Markers Colorectal Cancer Screening - mSEPT9
      • 2.10.1 Feasibility Study for Performance of Septin 9 in Plasma From Cases With Colorectal Cancer and Controls With Non-Diseased, Non-Colorectal Disease and Non-Colorectal Cancers
    • 2.11 Disease Specific Markers ProstaCheck
      • 2.11.1 ProstaCheck Blood Tests To Identify Prostate Cancer
    • 2.12 Disease Specific Markers VASCLIR
      • 2.12.1 Peripheral Artery Disease Diagnostic Test Clinical Study
  • 3 Recent Developments
    • 3.1 Product News
      • 3.1.1 Jun 03, 2009: bioTheranostics Presents Molecular Diagnostic Test Clinical Data At ASCO
      • 3.1.2 Jun 02, 2009: Prometheus Presents Clinical Findings Of Diagnostic Tests At DDW
      • 3.1.3 May 28, 2009: Caris Diagnostics Expands Target GI Colon Tumor Testing Panel To Incorporate BRAF Mutation Analysis
      • 3.1.4 May 28, 2009: Genomic Health's Oncotype DX Breast Cancer Test Treats More Than 100,000 Breast Cancer Patients Globally
      • 3.1.5 May 28, 2009: Nanosphere To Present Cancer Related Data At ASCO 2009 Annual Meeting
      • 3.1.6 May 28, 2009: Power3 Medical Products Presents NuroPro Blood Test
      • 3.1.7 May 27, 2009: ExonHit Therapeutics Signs License Agreement With Institut Gustave Roussy For Novel Breast Cancer Diagnostic Assay
      • 3.1.8 May 27, 2009: Monogram To Present Studies On HERmark Breast Cancer Assay And VeraTag Technology At The 45th ASCO Meeting
      • 3.1.9 May 21, 2009: Siemens Corporate Research Announces RAPID2 System For Biomarker Discovery
      • 3.1.10 May 18, 2009: AspenBio Pharma Presents Clinical Data Of AppyScore Diagnostic Blood Marker At 2009 Annual Meeting Of SAEM
      • 3.1.11 May 14, 2009: Genomic Health, Inc Announces Positive Results From The Landmark QUASAR Validation Study And Plans To Launch The Test In Early 2010
      • 3.1.12 May 13, 2009: Clinical Data Doubles The Number Of Genes To Enhance FAMILION Long QT Syndrome Test
      • 3.1.13 May 11, 2009: Transgenomic And Power3 Medical Introduces NuroPro Test For Alzheimer's Diseases
      • 3.1.14 May 05, 2009: Biosite Incorporated Initiates Nationwide Recall For Cardiac Marker Test
      • 3.1.15 May 05, 2009: Clarient Launches Insight Dx Breast Cancer Profile
      • 3.1.16 May 04, 2009: China Sky One Medical's Sudden Cardiac Death (SCD) Early Examination Kit Research Achieves A Significant Breakthrough
      • 3.1.17 Apr 30, 2009: Response Genetics Anounces The Expansion Of ResponseDX: Lung And ResponseDX: Colon Genetic Tests To Include Additional Biomarkers Associated With Chemotherapy Response
      • 3.1.18 Apr 27, 2009: China Medical Technologies Announces State Food And Drug Administration Approval For Bladder Cancer FISH Probe
      • 3.1.19 Apr 21, 2009: Abraxis Bioscience Reports Data Showcasing Its SPARC Biomarker At AACR Annual Meeting
      • 3.1.20 Apr 21, 2009: Maine Standards Company Launches New VALIDATE Cardiac Marker Test Set
      • 3.1.21 Apr 20, 2009: Genomic Health Presents Results Of International Multi-Center Study Evaluating Oncotype DX In Japan
      • 3.1.22 Apr 14, 2009: Genomic Health Reports Positive Preliminary Results From QUASAR Validation Study Of Oncotype DX Colon Cancer Assay
      • 3.1.23 Apr 14, 2009: Olympus Receives FDA Clearance To Market CEA Tumor Marker Assay In US
      • 3.1.24 Apr 14, 2009: SenoRx To Introduce StarchMark Biopsy Site Marker At American Society Of Breast Surgeonsz
      • 3.1.25 Mar 24, 2009: Siemens Highlights Cardiac-Specific C- Reactive Protein (hsCRP) Test At ACC 2009
      • 3.1.26 Mar 16, 2009: Prometheus Announces New York State Approval For Prometheus IBS Diagnostic Test For Irritable Bowel Syndrome
      • 3.1.27 Mar 12, 2009: AspenBio Pharma To File FDA 510(k) Application For AppyScore
      • 3.1.28 Mar 03, 2009: Cambridge Heart Studies Microvolt T-Wave Alternans Test Ability To Predict Risk Of Sudden Cardiac Arrest
      • 3.1.29 Feb 26, 2009: CombiMatrix's Investigational Comprehensive Cancer Array (CCA) Test Shows Postive Clinical Results
      • 3.1.30 Feb 25, 2009: Epigenomics AG Licenses Biomarker For Development Of Prostate Cancer Test To Quest Diagnostics
      • 3.1.31 Feb 25, 2009: OLIGOMERIX Develops Novel Biomarkers For Alzheimer's Disease
      • 3.1.32 Feb 12, 2009: Vermillion Receives Notice Of Issuance Of US Patent For Hepcidin As A Biomarker For Ovarian Cancer
      • 3.1.33 Feb 11, 2009: Fujirebio Diagnostics` Risk Of Ovarian Malignancy Algorithm(ROMA) In Combination With Biomarker Demonstrates Accuracy In Detecting Ovarian Cancer
      • 3.1.34 Feb 11, 2009: Metabolon's Biochemical Profiling Technology To Identify Prostate Cancer Progression
      • 3.1.35 Feb 10, 2009: CombiMatrix To Present Preliminary Data On Cancer Screening Test
      • 3.1.36 Feb 10, 2009: For National Access To FAMILION Genetic Tests, Clinical Data Inc Signs Contract
      • 3.1.37 Feb 04, 2009: EXACT Sciences Receives Key Patent Covering Vimentin Gene For Colorectal Cancer Screening
      • 3.1.38 Jan 29, 2009: Polymedco Announced The Direct Availability Of The BTA Stat Test
      • 3.1.39 Jan 28, 2009: Micro Rap Ltd Reports Successfull Completion Of Trial Of Diagnostic Kit For Type-1 Diabetes
      • 3.1.40 Jan 26, 2009: Fujirebo Diagnostics Reports Published Pivotal Data For First Biomarker Combination Test
      • 3.1.41 Jan 22, 2009: China Medical Technologies Receives SFDA Approval For Cervical Cancer FISH Probe And Prenatal FISH Probe
      • 3.1.42 Jan 22, 2009: Miraculins Announces Successful Completion Of Testing Of P2V Immunoassay
      • 3.1.43 Jan 20, 2009: AspenBio Pharma Discloses Clinical Study Preliminary Results of AppyScore
      • 3.1.44 Jan 16, 2009: Rosetta Genomics And Collaborators Identified Candidate MicroRNA Biomarkers In Serum
      • 3.1.45 Jan 13, 2009: Clarient Announces Launch Of Prostate Cancer Gene Expression Test
      • 3.1.46 Jan 13, 2009: IRIS International Announces IRB Approval To Begin The First Stage Of Its NADiA ProsVue Clinical Study
      • 3.1.47 Jan 12, 2009: QUASAR Clinical Study Commenced For Oncotype DX Colon Cancer Assay
      • 3.1.48 Jan 08, 2009: NuGEN's Ovation Systems Help Almac To Broaden Gene Expression
      • 3.1.49 Jan 08, 2009: Zetiq Successfully Completes The First Arm Of Success In Cervical Clinical Trial
      • 3.1.50 Jan 06, 2009: Xenomics Presents HPV Test Based On Proprietary Technology At 52nd All India Congress Of Obstetrics & Gynecology
    • 3.2 Product Approvals
      • 3.2.1 Apr 27, 2009: China Medical Technologies Announces State Food And Drug Administration Approval For Bladder Cancer FISH Probe
      • 3.2.2 Apr 14, 2009: Olympus Receives FDA Clearance To Market CEA Tumor Marker Assay In US
      • 3.2.3 Jan 22, 2009: China Medical Technologies Receives SFDA Approval For Cervical Cancer FISH Probe And Prenatal FISH Probe
      • 3.2.4 Nov 12, 2008: China Medical Technologies Receives SFDA Approval For Breast Cancer HER-2 FISH Probe
    • 3.3 Clinical Trials
      • 3.3.1 Jun 03, 2009: bioTheranostics Presents Molecular Diagnostic Test Clinical Data At ASCO
      • 3.3.2 Jun 02, 2009: Prometheus Presents Clinical Findings Of Diagnostic Tests At DDW
      • 3.3.3 May 28, 2009: Power3 Medical Products Presents NuroPro Blood Test
      • 3.3.4 May 28, 2009: Genomic Health's Oncotype DX Breast Cancer Test Treats More Than 100,000 Breast Cancer Patients Globally
      • 3.3.5 May 28, 2009: Nanosphere To Present Cancer Related Data At ASCO 2009 Annual Meeting
      • 3.3.6 May 27, 2009: Monogram To Present Studies On HERmark Breast Cancer Assay And VeraTag Technology At The 45th ASCO Meeting
      • 3.3.7 May 18, 2009: AspenBio Pharma Presents Clinical Data Of AppyScore Diagnostic Blood Marker At 2009 Annual Meeting Of SAEM
      • 3.3.8 May 14, 2009: Genomic Health, Inc Announces Positive Results From The Landmark QUASAR Validation Study And Plans To Launch The Test In Early 2010
      • 3.3.9 Apr 21, 2009: Abraxis Bioscience Reports Data Showcasing Its SPARC Biomarker At AACR Annual Meeting
      • 3.3.10 Apr 20, 2009: Genomic Health Presents Results Of International Multi-Center Study Evaluating Oncotype DX In Japan
      • 3.3.11 Apr 14, 2009: Genomic Health Reports Positive Preliminary Results From QUASAR Validation Study Of Oncotype DX Colon Cancer Assay
      • 3.3.12 Mar 03, 2009: Cambridge Heart Studies Microvolt T-Wave Alternans Test Ability To Predict Risk Of Sudden Cardiac Arrest
      • 3.3.13 Feb 26, 2009: CombiMatrix's Investigational Comprehensive Cancer Array (CCA) Test Shows Postive Clinical Results
      • 3.3.14 Feb 11, 2009: Metabolon's Biochemical Profiling Technology To Identify Prostate Cancer Progression
      • 3.3.15 Feb 11, 2009: Fujirebio Diagnostics` Risk Of Ovarian Malignancy Algorithm(ROMA) In Combination With Biomarker Demonstrates Accuracy In Detecting Ovarian Cancer
      • 3.3.16 Feb 10, 2009: CombiMatrix To Present Preliminary Data On Cancer Screening Test
      • 3.3.17 Jan 28, 2009: Micro Rap Ltd Reports Successfull Completion Of Trial Of Diagnostic Kit For Type-1 Diabetes
      • 3.3.18 Jan 26, 2009: Fujirebo Diagnostics Reports Published Pivotal Data For First Biomarker Combination Test
      • 3.3.19 Jan 22, 2009: Miraculins Announces Successful Completion Of Testing Of P2V Immunoassay
      • 3.3.20 Jan 20, 2009: AspenBio Pharma Discloses Clinical Study Preliminary Results of AppyScore
      • 3.3.21 Jan 16, 2009: Rosetta Genomics And Collaborators Identified Candidate MicroRNA Biomarkers In Serum
      • 3.3.22 Jan 13, 2009: IRIS International Announces IRB Approval To Begin The First Stage Of Its NADiA ProsVue Clinical Study
      • 3.3.23 Jan 12, 2009: QUASAR Clinical Study Commenced For Oncotype DX Colon Cancer Assay
      • 3.3.24 Jan 08, 2009: Zetiq Successfully Completes The First Arm Of Success In Cervical Clinical Trial
  • 4 Appendix
    • 4.1 Methodology
      • 4.1.1 Coverage
      • 4.1.2 Secondary Research
      • 4.1.3 Primary Research
      • 4.1.4 Expert Panel Validation
    • 4.2 Contact Us
    • 4.3 About Global Markets Direct
    • 4.4 Disclaimer
  • 1 List of Tables
    • Table 1: Disease Specific Markers Clinical Trial By Equipment Type
    • Table 2: Disease Specific Markers Clinical Trials By Trial Phase and Trial Status
    • Table 3: Disease Specific Markers Pipeline Products By Development Stage
    • Table 4: Disease Specific Markers Pipeline Products By Therapy Area
    • Table 5: Disease Specific Markers Pipeline Products By News Summary
    • Table 6: B7-H4 (DD-O110) assay - B7-H4 Is A Novel Membrane-Bound Protein And a Candidate Serum And Tissue Biomarker For Ovarian Cancer
    • Table 7: B7-H4 (DD-O110) assay - B7-H4 Is Over-Expressed In Early-Stage Ovarian Cancer And Is Independent Of CA125 Expression
    • Table 8: Spondin-2 (DD-P108) assay - Evaluation Of The Novel Serum Marker, Spondin 2, For Diagnosis And Early Detection Of Ovarian Cancer
    • Table 9: DcR3 (DD-C248) assay - Evaluation Of DcR3 For Diagnosis And Early Detection Of Ovarian Cancer
    • Table 10: TRAIL-R2 assay - Trails To Evaluate The Safety And Pharmacology Of Trail-R2 Monoclonal Antibody In Patients With Advanced Tumors
    • Table 11: Colorectal Cancer Screening - mSEPT9 - Feasibility Study for Performance of Septin 9 in Plasma From Cases With Colorectal Cancer and Controls With Non-Diseased, Non-Colorectal Disease and Non-Colorectal Cancers
    • Table 12: ProstaCheck - ProstaCheck Blood Tests To Identify Prostate Cancer
    • Table 13: VASCLIR - Peripheral Artery Disease Diagnostic Test Clinical Study
  • 1.2 List of Figures
    • Figure 1: Global Markets Direct Methodology